Skip to main content
. 2022 Dec 17;14(12):2817. doi: 10.3390/v14122817

Table 2.

Comorbidities and sites of thromboembolic events in the study population.

Site of Thromboembolic Event
DVT *
12/58 (20.6%)
PE ** “De Novo”
21/58
(36.2%)
DVT + PE
3/58
(5.1%)
Stroke
11/58
(18.9%)
Acute Myocardial Infarction
5/58
(8.6%)
Arterial Thrombosis,
Excluding
MI and
Stroke
4/58
(6.8%)
DVT + PE + Arterial Thrombosis + Acute Myocardial Infarction
1/58
(1.7%)
PE + Cerebral Thrombosis
1/58
(1.7%)
SEX n° (%)
Male 36 (62) 7 18 3 2 4 1 1 0
Female 22 (37.9) 5 3 0 9 1 3 0 1
COMORBIDITIES
Hypertension 4 1 2 - 1 - - - -
Obesity 6 1 5 - - - - - -
Diabetes 3 1 1 - - 1 - - -
Pregnancy 3 1 - - 1 1 - - -
Neoplasia 3 2 1 - - - - - -
Coagulation disorders 3 1 - - - - 2 - -
Smokers 4 - 2 - - 2 - - -
Obesity + hypertension 3 - 3 - - - - - -
Hypertension + smoking habit 3 - 2 - - - - 1 -
Hypertension + obesity + smoking habit 1 - 1 - - - - - -
Autoimmune diseases 1 - 1 - - - - - -
Immunosuppression 5 4 1 - - - - - -
Ischemic heart disease 3 - 1 - - 1 - 1 -
Dyslipidemia 3 1 2 - - - - - -
Chronic kidney disease 1 - 1 - - - - - -
Asthma/COPD *** 3 1 2 - - - - - -
No comorbidities/not reported 25 4 5 3 8 2 2 - 1
Drug users 2 - - - 1 1 - - -
Outcome (dead) 3
(25%)
7
(33.3%)
1
(33.3%)
1
(9%)
3
(60%)
1
(20%)
0 0

* DVT—deep venous thrombosis ** PE—pulmonary embolism. *** Chronic obstructive pulmonary disease.